Illumina Stock Forecast, Price & News

Illumina's stock was trading at $246.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ILMN shares have increased by 19.0% and is now trading at $292.70.
View which stocks have been most impacted by COVID-19.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 3 sell ratings, 9 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Illumina.

Illumina is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Illumina.

Illumina, Inc. (NASDAQ:ILMN) issued its quarterly earnings data on Thursday, October, 29th. The life sciences company reported $1.02 EPS for the quarter, beating the Zacks' consensus estimate of $0.77 by $0.25. The life sciences company had revenue of $794 million for the quarter, compared to analysts' expectations of $713.97 million. Illumina had a net margin of 20.67% and a return on equity of 19.13%. The business's revenue for the quarter was down 12.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.93 earnings per share.
View Illumina's earnings history.

17 brokerages have issued 12 month price objectives for Illumina's shares. Their forecasts range from $280.00 to $400.00. On average, they expect Illumina's stock price to reach $323.59 in the next year. This suggests a possible upside of 10.6% from the stock's current price.
View analysts' price targets for Illumina.

Illumina saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 4,820,000 shares, an increase of 23.3% from the September 30th total of 3,910,000 shares. Based on an average trading volume of 1,430,000 shares, the short-interest ratio is currently 3.4 days. Approximately 3.3% of the shares of the company are short sold.
View Illumina's Short Interest.

Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Waters (WAT), Charles River Laboratories International (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Pacific Biosciences of California (PACB), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), The Walt Disney (DIS), PayPal (PYPL), salesforce.com (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Illumina's stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (0.67%), Douglas Lane & Associates LLC (0.24%), TCW Group Inc. (0.19%), KAMES CAPITAL plc (0.12%), DAVENPORT & Co LLC (0.10%) and Waverton Investment Management Ltd (0.08%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina.

ILMN stock was sold by a variety of institutional investors in the last quarter, including First Hawaiian Bank, Envestnet Asset Management Inc., TCW Group Inc., CIBC Private Wealth Group LLC, Gateway Investment Advisers LLC, Toronto Dominion Bank, WINTON GROUP Ltd, and Standard Life Aberdeen plc. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Sam Samad, and Susan H Tousi.
View insider buying and selling activity for Illumina.

ILMN stock was bought by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC, DekaBank Deutsche Girozentrale, ARK Investment Management LLC, BP PLC, Bradley Foster & Sargent Inc. CT, KBC Group NV, Robeco Institutional Asset Management B.V., and Artemis Investment Management LLP.
View insider buying and selling activity for Illumina.

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ILMN stock can currently be purchased for approximately $292.70.

Illumina has a market capitalization of $42.73 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis. Illumina employs 7,700 workers across the globe.

The official website for Illumina is www.illumina.com.

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]